Key result
Sulfonylurea drugs may increase the risk of cardiac events in patients with type 2 diabetes, despite the known vascular benefits of maintaining euglycemia.
Why the study?
Do sulfonylurea drugs increase the risk of cardiac events in patients with type 2 diabetes?
Do sulfonylurea drugs increase the risk of cardiac events in patients with type 2 diabetes?
This article discusses the potential cardiovascular risks associated with sulfonylurea use in patients with type 2 diabetes.
Supports caution with sulfonylureas in T2D; leaves open causality and needs randomized confirmation.
Sulfonylureas have been a mainstay for maintaining glucose control in type 2 diabetes. There is ample evidence that maintaining euglycemia decreases the risk of vascular disease in patients with type 2 diabetes; however, there is also evidence that sulfonylurea drugs may actually cause
No takes yet. Share an insight, caveat, or question.
David S.H. Bell (2006) studied this question. Sulfonylurea drugs may increase the risk of cardiac events in patients with type 2 diabetes, despite the known vascular benefits of maintaining euglycemia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: